peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GC-C agonist

Plecanatide

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

Plecanatide is categorized here as an approved therapeutic peptide with a cyclic structure.

Sources for this introduction: [1]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Plecanatide is categorized here as an approved therapeutic peptide with a cyclic structure.

Sources[1]pubmedA targeted partial reduction cyanylation strategy coupled with HRMS for accurate disulfide bridge mapping in disulfide rich cyclic peptides.The method was evaluated using representative approved cyclic peptide therapeutics, specifically Linaclotide, Plecanatide, and Ziconotide.[1]pubmedA targeted partial reduction cyanylation strategy coupled with HRMS for accurate disulfide bridge mapping in disulfide rich cyclic peptides.The methodology was successfully validated using Linaclotide, Plecanatide, and Ziconotide, which contain three, two, and three disulfide bridges, respectively.
Source records
2
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The method was evaluated using representative approved cyclic peptide therapeutics, specifically Linaclotide, Plecanatide, and Ziconotide.”

    A targeted partial reduction cyanylation strategy coupled with HRMS for accurate disulfide bridge mapping in disulfide rich cyclic peptides. · Abstract

    pubmed:42242129:f6bca2a54250:f6bca2a54250
  2. supports · Source-backed record
    “The methodology was successfully validated using Linaclotide, Plecanatide, and Ziconotide, which contain three, two, and three disulfide bridges, respectively.”

    A targeted partial reduction cyanylation strategy coupled with HRMS for accurate disulfide bridge mapping in disulfide rich cyclic peptides. · Abstract

    pubmed:42242129:f6bca2a54250:f6bca2a54250

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, mechanism, regulatory, safety
  • 4 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (2), assurance_score_below_0.72 (1), extraction_ambiguity (4), high_risk_requires_regulatory_or_two_independent_sources (1), no_direct_support (3)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. A targeted partial reduction cyanylation strategy coupled with HRMS for accurate disulfide bridge mapping in disulfide rich cyclic peptides. ↗

    pubmed · published 2026-08-30 · retrieved 2026-08-27T11:48:55Z

Publication history and provenance

Version 2 · Automated assessment · 2026-08-27T11:48:55Z

8f025ece48e2612b412defe8b105f4dc66ed1232583259c599276d2ace2ed137